Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VNRXBullishCorporate Developmentsnews

High materiality7/10

Volition and Missionpharma pursue LFT NETosis rollout for neonatal sepsis

Oct 27, 2026, 8:00 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive near-term sentiment from a strategic partnership and potential TAM expansion; however, the LOI is non-binding, so actual revenue impact depends on subsequent terms, regulatory clearances, and successful pilot data.

AI summary

What happened, with direct paths to the underlying reporting

VolitionRx announced a non-binding LOI with Missionpharma to explore a finger-prick LFT for NETosis, initially focused on neonatal sepsis. The collaboration may broaden Volition’s addressable market by enabling decentralized testing in LMICs and humanitarian settings, with UN partners involved through Missionpharma. While the LOI is non-binding, favorable terms or pilot data could accelerate commercialization.

Volition signs non-binding LOI with Missionpharma for LFT NETosis.
LOI targets neonatal sepsis triage; expands TAM in LMICs and humanitarian settings.
LFT prototype correlates with Nu.Q NETs in sepsis, enabling decentralized testing.
Missionpharma to assist with low-cost manufacturing, clinical studies, and distribution.
Initial clinical use: triage and prognostication for neonatal sepsis; 2.3M newborn deaths/year.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Volition and Missionpharma pursue LFT NETosis rollout for neonatal sepsis

VolitionRx H1 2026 revenue up 112%, expanding clinical and commercial ops